Kite to Present at August 2017 Investor Conference

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE), a leading cell therapy company, today announced that management will present at the Canaccord Genuity 37th Annual Growth Conference on Wednesday, August 9, 2017 at 2:00 pm Eastern Time in Boston, MA.

A live audio webcast of the event will be available on the Investors section of Kite's website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.

About Kite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170801005609/en/

Kite Contacts:
Christine Cassiano
SVP, Corporate Communications & Investor Relations
[email protected]
or
Greg Mann
VP, Investor Relations
[email protected]

Source: Kite Pharma, Inc.

You May Also Be Interested In

• Gelum Resources closes $4.3M private placement, hires geophysics firm
• Rocket One Regains Full Nasdaq Compliance with Minimum Bid Price Requirement
• FuelCell Energy signs deal with Fit Energy for up to 380 MW of power